GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Stemtech Corp (OTCPK:STEK) » Definitions » EV-to-EBITDA

STEK (Stemtech) EV-to-EBITDA : -2.02 (As of May. 07, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Stemtech EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Stemtech's enterprise value is $6.16 Mil. Stemtech's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was $-3.06 Mil. Therefore, Stemtech's EV-to-EBITDA for today is -2.02.

The historical rank and industry rank for Stemtech's EV-to-EBITDA or its related term are showing as below:

STEK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -20.79   Med: -1.46   Max: 140.56
Current: -2.02

During the past 4 years, the highest EV-to-EBITDA of Stemtech was 140.56. The lowest was -20.79. And the median was -1.46.

STEK's EV-to-EBITDA is ranked worse than
100% of 730 companies
in the Drug Manufacturers industry
Industry Median: 13.635 vs STEK: -2.02

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-07), Stemtech's stock price is $0.022. Stemtech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.060. Therefore, Stemtech's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Stemtech EV-to-EBITDA Historical Data

The historical data trend for Stemtech's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stemtech EV-to-EBITDA Chart

Stemtech Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
- 64.25 -1.26 50.51

Stemtech Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.07 50.51 -27.41 -3.23 -2.77

Competitive Comparison of Stemtech's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Stemtech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stemtech's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Stemtech's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Stemtech's EV-to-EBITDA falls into.


;
;

Stemtech EV-to-EBITDA Calculation

Stemtech's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=6.161/-3.057
=-2.02

Stemtech's current Enterprise Value is $6.16 Mil.
Stemtech's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stemtech  (OTCPK:STEK) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Stemtech's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.022/-0.060
=At Loss

Stemtech's share price for today is $0.022.
Stemtech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.060.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Stemtech EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Stemtech's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Stemtech Business Description

Traded in Other Exchanges
N/A
Address
4851 Tamiami Trail North, Suite 200, Naples, FL, USA, 34103
Stemtech Corp is a nutraceutical company. Its products enhance and support the work of the body's stem cells by releasing more stem cells, helping to circulate them in the blood and migrate them into tissues, where perform their daily function of renewal for optimal health. It markets its products under the following brands: RCM System, stemrelease3, Stemflo MigraStem, OraStem (Oral Health Care), and D-Fuze. Geographically, it derives a majority of its revenue from the Americas.
Executives
Charles Stuart Arnold director 520 BRICKELL KEY DR #1607, MIAMI FL 33131
Mindshare Holdings, Inc. 10 percent owner 419 BOSTWICK LANE, GAITHERSBURG MD 20878
Darryl V Green director 300 SIXTH AVENUE, PITTSBURGH PA 15222
John William Meyer director 10370 USA TODAY WAY, MIRAMAR FL 33025
Benjamin Nathaniel Kaplan director 13005 CORONOADO LANE, NORTH MIAMI FL 33181